Activated Protein C Resistance: Effect of Platelet Activation, Platelet-Derived Microparticles, and Atherogenic Lipoproteins
Open Access
- 1 June 1999
- journal article
- Published by American Society of Hematology in Blood
- Vol. 93 (11) , 3792-3797
- https://doi.org/10.1182/blood.v93.11.3792
Abstract
Plasma and platelet factor Va represent different substrates for activated protein C (APC). In this study, we have measured platelet-dependent APC resistance and the effect of aspirin and a platelet glycoprotein IIbIIIa antagonist (GR144053F) on this phenomenon. In platelet rich plasma (PRP), progressive APC resistance was observed with increasing platelet activation. APC sensitivity ratios of 1.8, 1.7, and 1.4 were observed after platelet activation with thrombin receptor activating peptide (TRAP), collagen, and A23187, respectively. Ultracentrifugation at 77,000g for 1 hour abolished APC resistance indicating that the phenotype is associated exclusively with the platelet membrane. APC resistance was not observed in the presence of phosphatidylcholine-phosphatidylserine (PCPS) vesicles or purified human plasma lipoproteins. APC resistance was observed in the presence of platelet-derived microparticles, but to a lesser degree than that in the presence of activated platelets. The platelet-dependent APC resistance phenotype was also observed when endogenous APC was generated by Protac (American Diagnostica, Inc, Greenwich, CT). In vitro inhibition of platelet activation with aspirin had no effect, but the fibrinogen receptor antagonist, GR144053F, inhibited platelet-dependent APC resistance. These results indicate that platelet activation results in an APC-resistant phenotype comparable to that observed in the plasma of patients with factor V gene mutations affecting critical APC cleavage sites. This suggests that platelet activation at the site of endothelial damage downregulates a critical natural anticoagulant mechanism. The antithrombotic effect of aspirin may be due to an indirect effect on platelet-dependent APC resistance with reduced platelet retention within a developing thrombus. The more potent antithrombotic effect of glycoprotein IIbIIIa antagonists may in addition be the result of reduced platelet factor Va expression and modulation of the platelet-dependent APC resistance phenotype.Keywords
This publication has 21 references indexed in Scilit:
- Atherogenic Lipoproteins Support Assembly of the Prothrombinase Complex and Thrombin Generation: Modulation by Oxidation and Vitamin EBlood, 1998
- False-positive activated protein C (APC) sensitivity ratio caused by freezing and by contamination of plasma with plateletsThrombosis Research, 1995
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy MenNew England Journal of Medicine, 1995
- Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.Journal of Clinical Investigation, 1994
- Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosisThe Lancet, 1994
- Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor VThe Lancet, 1994
- Activated protein C resistance caused by Arg506Gln mutation in factor VaThe Lancet, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.Proceedings of the National Academy of Sciences, 1993